Developer of 3D-printed drug delivery platforms for targeted pharmaceutical agents. The company focuses on creating minimally invasive methods for delivering medication directly. It utilizes its technology to provide drugs locally, avoiding negative systemic effects. The company's patented technology aims to transform patient care through innovative therapies. Founded in 2018, headquartered in New York City, United States. The company has raised $10.6M in funding at the seed stage. BioSapien operates in the Nanotechnology, Drug Delivery sectors. The company focuses on Cancer Treatment, Patches. Notable investors include JPIN, SOSV, Hikma Ventures, Side Door Ventures, MicroVentures, DC Capital Ventures, among others. The company is categorized under High Tech > Nanotechnology; Life Sciences > Drug Delivery.
← All startups
BioSapien
SeedDeveloper of 3D-printed drug delivery platforms for targeted pharmaceutical agents. The company focuses on creating minimally invasive methods for delivering medication directly. It utilizes its technology to provide drugs locally, avoiding negative systemic effects. The company's patented technology aims to transform patient care through innovative therapies. Founded in 2018, headquartered in New York City, United…
About
Business model
Nanotechnology > Nanoenabled Products > Life Science > Drug Delivery > Encapsulation > Cancer Treatment,
Drug Delivery > Patches
Institutional investors
JPINSOSVHikma VenturesSide Door VenturesMicroVenturesDC Capital VenturesNational Science FoundationGlobal VenturesDARA HoldingsGolden Gate VenturesHikma PharmaceuticalsInfinity Capital VenturesBeni Venture CapitalKartik Garg
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ See who's investing in High Tech — full fund directory with check size and geography.